Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Time ending
研究概览
简要总结
By dynamically observing the changes of echocardiogram and biomarkers in breast cancer patients using trastuzumab, evaluate the effect of trastuzumab on cardiac function; determine the sensitivity of echocardiography and biomarker indicators And specificity, explore effective and specific early warning indicators, and provide technical support for the evaluation of the cardiac safety of anti-tumor drugs.
详细描述
Thirty female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase), follow-up echocardiography and biomarkers at 1 month, 3 months and 6 months after chemotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with breast cancer (18-70 years old)
- •Patients who are planning to undergo trastuzumab for the first time
排除标准
- •Organic heart disease such as coronary heart disease, heart valve disease, cardiomyopathy
- •liver and kidney failure
- •severe cerebrovascular disease
- •chronic obstructive pulmonary disease
- •rheumatic immune system disease
- •other tumors
研究组 & 干预措施
Women with breast cancer using trastuzumab
干预措施: Trastuzumab (Drug)
结局指标
主要结局
Time ending
时间窗: 6 months
180 days after chemotherapy
次要结局
未报告次要终点